| Volume: | 9,906,506 |
|---|---|
| Day's Low: | $23.90 |
| 52-wk Low: | $17.23 |
| Previous Close: | $23.96 |
| Dividend: | $0.32 |
| Market Cap: | 47,464,300 |
| Avg Volume: | 26,995,700 |
|---|---|
| Day's High: | $24.40 |
| 52-wk High: | $26.62 |
| Open Price: | $24.10 |
| Yield: | 5.34% |
| P/E (Forward): | 10.84 |
| 11:56 AM | 2/9/2010 | UK Body Says Novartis, Bristol Cancer Drugs Too Expensive |
| 5:58 PM | 2/3/2010 | Ex-Bristol-Myers Employee Charged With Stealing Trade Secrets |
| 2:01 PM | 2/1/2010 | SUBSCRIBERS: FDA, Bristol-Myers News Already Reported |
| 4:24 PM | 1/29/2010 | CORRECT(1/28): Bristol-Myers CEO: 'We're Not For Sale' |
| 3:18 PM | 1/29/2010 | UPDATE:FDA Warns Doctors About Liver Risk With Bristol's Videx |
| 3:03 PM | 1/29/2010 | CORRECT: FDA Warns About Liver Risk With Bristol's Videx |
| 1:16 PM | 1/28/2010 | 2nd UPDATE: Bristol, Lilly 4Q Sales Up; Resolve Drug Dispute |
| 2/9/2010 | Pfizer Off 2% As 2010 Targets Miss; Posts Revised 2012 Targets (Barrons.com) |
| 2/9/2010 | How Much Should Cancer Drugs Cost? (WSJ.com) |
| 2/9/2010 | Avoid a few key mistakes, and you'll lose less money. (The Motley Fool) |
| 2/5/2010 | Why Pharma's Patent Cliff Is Good News for Pharmacies (WSJ.com) |
| 2/4/2010 | Cost Cuts Boost Corporate Net (WSJ.com) |
| 2/4/2010 | Biotech investors embrace risk ... sort of. (The Motley Fool) |
| 2/4/2010 | Medco buys in to personalized medicine. (The Motley Fool) |
| 2/3/2010 | Pfizer Net Doubles on '08 Charges (WSJ.com) |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.47 | 0.46 | 2.17 |
| EPS, GAAP | 4.04 | 0.63 | 541.27 |
| Consensus Estimate | 0.43 | 0.41 | 4.88 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.03 | 1.85 | 9.73 |
| EPS, GAAP | 1.92 | 2.63 | -27.00 |
| Consensus Estimate | 1.88 | NA | NA |
| BMY | Industry Average | |
| P/E (TTM) | 12.48 | 14.70 |
| P/E (Forward) | 10.84 | 12.60 |
| PEG Ratio | 1.14 | 1.45 |
| Price/Sales | 2.25 | 2.51 |
| Beta | 0.71 | 0.69 |